Grifols is one of the world's leading specialty plasma therapeutics companies, developing, manufacturing, and distributing biological medicines derived from human plasma proteins. The company generates revenue primarily through plasma-derived pharmaceutical products such as immunoglobulins, coagulation factors, and albumin sold to hospitals and specialty pharmacies globally, supplemented by in vitro diagnostics for blood screening and transfusion medicine, as well as biological materials for research and manufacturing. Operating a fully vertically integrated value chain with plasma collection centers across the United States, Europe, Canada, and Egypt, along with multiple fractionation facilities, Grifols holds a top-three global position in plasma therapeutics and serves over 100 countries through a combination of direct sales, government contracts, and licensing arrangements.